1型糖尿病成人使用瞬感血糖监测的全国性纵向观察研究
基于瑞典国家糖尿病登记库的队列研究,纳入14,372名起始瞬感血糖监测(FM)并持续使用2年的1型糖尿病成人,与7,691名使用传统自我血糖监测(SMBG)的对照比较。经倾向评分和逆概率治疗加权平衡后,FM组HbA1c在15-24个月时较对照组多降低1.2 mmol/mol(-0.11%),基线HbA1c≥70 mmol/mol者多降低2.5 mmol/mol(-0.23%),严重低血糖风险降低21%(OR 0.79)。
要点
- FM使用与HbA1c小幅持续改善相关,基线HbA1c越高改善越明显。
- FM组严重低血糖事件风险较SMBG组降低21%(OR 0.79)。
- 基线HbA1c≤52 mmol/mol和53-69 mmol/mol亚组HbA1c变化亦显著。
核心结论
- 在这项大型队列中,FM使用与HbA1c小幅且持续的改善相关,在基线HbA1c较高者中最明显。
- FM使用者严重低血糖事件发生率低于使用SMBG进行血糖管理的对照个体。
研究设计与样本
- 基于瑞典国家糖尿病登记库的全国性纵向观察性队列研究。
- 纳入14,372名2016-2017年新注册FM并持续使用2年的1型糖尿病成人,以及7,691名同期使用SMBG的对照。
- 采用倾向评分和逆概率治疗加权(IPTW)平衡FM使用者与SMBG使用者。
主要发现
- 随访15-24个月时,FM组较对照组IPTW校正的HbA1c变化估计平均绝对差异为-1.2 mmol/mol(-0.11%)(95%CI -1.64[-0.15], -0.75[-0.07];p<0.0001)。
- 基线HbA1c≥70 mmol/mol(8.5%)者中,索引后15-24个月估计平均绝对差异为-2.5 mmol/mol(-0.23%)(95%CI -3.84[-0.35], -1.18[-0.11];p=0.0002)。
- 基线HbA1c≤52 mmol/mol(6.9%)和53-69 mmol/mol(7.0-8.5%)亚组的HbA1c变化亦显著。
- FM使用者严重低血糖发作风险较SMBG对照降低21%(OR 0.79[95%CI 0.69, 0.91];p=0.0014)。
临床怎么用
- 对1型糖尿病成人,尤其是基线HbA1c较高者,可考虑使用FM以小幅持续改善血糖控制。
- FM可能有助于降低严重低血糖风险,可与SMBG相比作为血糖管理选择之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this work was to evaluate changes in glycaemic control (HbA1c) and rates of severe hypoglycaemia over a 2 year period after initiation of flash glucose monitoring (FM) in type 1 diabetes. METHODS: Using data from the Swedish National Diabetes Registry, 14,372 adults with type 1 diabetes with a new registration of FM during 2016-2017 and with continued FM for two consecutive years thereafter, and 7691 control individuals using conventional self-monitoring of blood glucose (SMBG) during the same observation period, were included in a cohort study. Propensity sores and inverse probability of treatment weighting (IPTW) were used to balance FM users with SMBG users. Changes in HbA1c and events of severe hypoglycaemia were compared. RESULTS: After the start of FM, the difference in IPTW change in HbA1c was slightly greater in FM users compared with the control group during the follow-up period, with an estimated mean absolute difference of -1.2 mmol/mol (-0.11%) (95% CI -1.64 [-0.15], -0.75 [-0.07]; p < 0.0001) after 15-24 months. The change in HbA1c was greatest in those with baseline HbA1c ≥70 mmol/mol (8.5%), with the estimated mean absolute difference being -2.5 mmol/mol (-0.23%) (95% CI -3.84 [-0.35], -1.18 [-0.11]; p = 0.0002) 15-24 months post index. The change was also significant in the subgroups with initial HbA1c ≤52 mmol/mol (6.9%) and 53-69 mmol/mol (7.0-8.5%). Risk of severe hypoglycaemic episodes was reduced by 21% for FM users compared with control individuals using SMBG (OR 0.79 [95% CI 0.69, 0.91]; p = 0.0014)]. CONCLUSIONS/INTERPRETATION: In this large cohort, the use of FM was associated with a small and sustained improvement in HbA1c, most evident in those with higher baseline HbA1c levels. In addition, FM users experienced lower rates of severe hypoglycaemic events compared with control individuals using SMBG for self-management of glucose control.
引用
- Nathanson D, Svensson AM, Miftaraj M, et al. Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls. Diabetologia. 2021. PMID: 33774713. doi:10.1007/s00125-021-05437-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。